Start Time: 08:30 January 1, 0000 9:18 AM ET
Seres Therapeutics, Inc. (NASDAQ:MCRB)
Q1 2023 Earnings Conference Call
May 09, 2023, 08:30 AM ET
Company Participants
Eric Shaff - President and CEO
Terri Young - EVP, Chief Commercial and Strategy Officer
Lisa von Moltke - EVP and Chief Medical Officer
David Arkowitz - EVP, CFO and Head of Business Development
David Ege - EVP, Chief Technology Officer
Matthew Henn - EVP, Chief Scientific Officer
Carlo Tanzi - IR Officer
Conference Call Participants
Mark Breidenbach - Oppenheimer
Joseph Thome - Cowen
Tessa Romero - JPMorgan
John Newman - Canaccord Genuity
Stephen Sloan - Goldman Sachs
Keay Nakae - Chardan Capital Markets
Operator
Hello. My name is Chris, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Q1 2023 Seres Therapeutics Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
Dr. Carlo Tanzi, Investor Relations, you may begin.
Carlo Tanzi
Thank you, and good morning. Our press release for the company's first quarter 2023 financial results and a business update became available at 7.00 AM Eastern Time this morning and can be found in the Investors and News section of the company's Web site. We will also be reviewing new SER-155 Phase 1b study results and we have posted slides on our corporate Web site that will accompany our remarks.
I'd like to remind you that we'll be making forward-looking statements, including the timing of commercial launch, the available of VOWST, the commercial success of VOWST, the timing and results of clinical studies, the timing of additional clinical data, final study results, the ability for microbiome therapeutics to modulate microbiome and treat or prevent infection, our ability to achieve certain sales targets and the receipt of future milestones and debt tranches, and other statements which are not historical fact.
Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the Risk Factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so.
On today's call with prepared remarks, I'm joined by Eric Shaff, Seres' President and CEO; David Arkowitz, Chief Financial Officer; Dr. Lisa von Moltke, Chief Medical Officer; and Dr. Matthew Henn, Chief Scientific Officer. Additionally, Dr. Terri Young, Chief Commercial Officer; and Dr. Dave Ege, Chief Technology Officer, will also be available to answer your questions.